StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.57−0.08 (-1.50%)

Close on Nov 17, 2026Market cap $482.87MP/E –Yield –

Valneva total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Valneva's total debt was €184.06M at Jun 30, 2026. For fiscal 2025 it was €179.17M, down 4.4% from the year before. The highest annual figure on record is €187.37M in fiscal 2024.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025€179.17M-4.4%
FY2024Dec 31, 2024€187.37M+6.0%
FY2023Dec 31, 2023€176.85M+79.0%
FY2022Dec 31, 2022€98.81M+70.8%
FY2021Dec 31, 2021€57.83M+8.4%
FY2020Dec 31, 2020€53.36M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€184.06M+9.3%
Q1 FY2026Mar 31, 2026€182.33M+0.6%
Q4 FY2025Dec 31, 2025€179.17M-4.4%
Q3 FY2025Sep 30, 2025€167.72M-2.8%
Q2 FY2025Jun 30, 2025€168.39M-6.7%
Q1 FY2025Mar 31, 2025€181.18M-0.1%
Q4 FY2024Dec 31, 2024€187.37M+6.0%
Q3 FY2024Sep 30, 2024€172.58M+22.5%
Q2 FY2024Jun 30, 2024€180.42M+89.1%
Q1 FY2024Mar 31, 2024€181.45M+86.3%
Q4 FY2023Dec 31, 2023€176.85M+79.0%
Q3 FY2023Sep 30, 2023€140.86M+33.1%
Q2 FY2023Jun 30, 2023€95.41M+21.4%
Q1 FY2023Mar 31, 2023€97.39M+63.0%
Q4 FY2022Dec 31, 2022€98.81M+70.8%
Q3 FY2022Sep 30, 2022€105.86M+98.4%
Q2 FY2022Jun 30, 2022€78.60M–
Q1 FY2022Mar 31, 2022€59.74M–
Q4 FY2021Dec 31, 2021€57.83M–
Q4 FY2020Dec 31, 2020€53.36M–

More Valneva figures

See a number that looks wrong?